Donald Boyd, MD
Hematology & Oncology · Greenwich, CTNPI 1396826376
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,810 of the $64,578 with a category attached, or 74.0%. Merck accounts for 71.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $61,376 and has fallen 99.7% since, to $170 in 2024. Among hematology & oncology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $1009.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$46K
- Helsinn Therapeutics (U.S.), Inc.$12K
- Foundation Medicine, Inc.$5K
- Seagen Inc.$282
- AbbVie$136
- Incyte Corporation$125
- plus $160 from 4 others
What the payments were for
- Consulting fees$4,0006%
- Speaking & faculty fees$47,81074%
- Travel & lodging$10,47616%
- Food & beverage$1,8853%
- Education$4071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 41 | $46,335 |
| Helsinn Therapeutics (U.S.), Inc. | 9 | $12,064 |
| Foundation Medicine, Inc. | 5 | $5,476 |
| Seagen Inc. | 3 | $282 |
| AbbVie | 1 | $136 |
| Incyte Corporation | 1 | $125 |
| Astellas Pharma US Inc | 1 | $99 |
| Octapharma USA, Inc. | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$41,926
- AKYNZEO$11,765
- FOUNDATIONACT$5,446
- FOUNDATIONFOCUS$5,446
- FOUNDATIONONE CDX$5,446
- FOUNDATIONONE HEME$5,446
- FOUNDATIONONE$5,446
- Elahere$136
- JAKAFI$125
How this compares
$64,578 in reported general payments places this provider in the 90th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 37 | $560,523 |
| CalquenceAcalabrutinib Maleate | 32 | $471,514 |
| RevlimidLenalidomide | 16 | $248,023 |
| EliquisApixaban | 76 | $53,385 |
| Toremifene Citrate | 11 | $8,143 |
| Exemestane | 37 | $4,860 |
| Anastrozole | 193 | $3,552 |
| Letrozole | 45 | $1,299 |
| Raloxifene Hcl | 30 | $897 |
| Ondansetron OdtOndansetron | 29 | $565 |
| Dexamethasone | 24 | $547 |
| Allopurinol | 15 | $426 |
| Tamoxifen Citrate | 33 | $363 |
| Zolpidem Tartrate | 32 | $308 |
| Bicalutamide | 14 | $294 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Greenwich
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
- Justine RyuOrange$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.